DoD Pancreatic Cancer, Idea Development Award | W81XWH 22 PCARP IDA

Opportunity Information: Apply for W81XWH 22 PCARP IDA

The DoD Pancreatic Cancer Research Program (PCARP) Idea Development Award (FY22; Funding Opportunity Number W81XWH-22-PCARP-IDA) is a Department of Defense grant/cooperative agreement opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that aims to push pancreatic cancer research forward by funding bold, creative projects. The core purpose is to support innovative, high-risk/high-reward studies that may be too early or unconventional for other funding mechanisms but have the potential to produce critical discoveries, generate highly impactful datasets, and open up brand-new directions for the field. Even if a project is not expected to produce an immediate clinical application, applicants are expected to clearly explain how the work could meaningfully advance understanding of pancreatic cancer and, over time, contribute to improved patient outcomes.

A major review emphasis is on impact and originality. The program is looking for research that can make an important and distinct contribution, rather than work that simply adds another incremental step to what has already been published. Applicants need to spell out what changes if the project succeeds: what core problem gets solved, what bottleneck gets removed, or what new capability becomes possible for the pancreatic cancer research community and, ultimately, for patient care. In that same spirit, innovation is treated as a requirement, not a bonus. Competitive ideas may introduce a new paradigm, challenge prevailing assumptions, reframe a long-standing problem from a different angle, or apply genuinely creative approaches. Innovation can show up in the central concept, the experimental design, new tools or technologies, or clever adaptations of existing methods, but proposals that mainly extend prior work in a straightforward way are explicitly described as not meeting the innovation bar.

The award also places unusually strong emphasis on the research team. At least one person on the team must have demonstrated experience in pancreatic cancer research, typically evidenced through recent publications and prior or current funding. This requirement signals that the program wants ambitious ideas, but not at the expense of disease-specific expertise. The inclusion of a biostatistician is encouraged, reflecting the expectation that projects will be designed with appropriate rigor, power considerations, and analysis plans, especially when generating datasets meant to guide future investigations.

Although the award supports early-stage, idea-driven science, proposals must still be grounded in preliminary data. Importantly, the preliminary results do not have to come directly from pancreatic cancer experiments; they can come from outside the pancreatic cancer field as long as the proposed project itself is directly relevant to pancreatic cancer. The intent is to allow strong, transferable evidence (for example, proof-of-concept in another cancer type, a validated platform technology, or strong mechanistic data in a related biological system) to justify taking a calculated leap into pancreatic cancer. Alongside the preliminary data expectation, the application must be built on a clear scientific rationale supported by thoughtful reasoning and a critical reading of the literature, so that reviewers can see why the idea is plausible and why it is positioned to produce meaningful knowledge even if it is exploratory.

A notable feature of this funding opportunity is an optional Partnering PI track designed to support career development for early-career investigators entering pancreatic cancer research. Under this option, an experienced pancreatic cancer investigator serves as the Initiating PI (and mentor) and partners with an Early-Career Investigator who serves as the Partnering PI. The Initiating PI is expected to actively mentor and collaborate with the early-career partner in a way that supports their long-term trajectory in pancreatic cancer research, not simply provide a letter of support. Administratively, the Initiating PI takes primary responsibility for submitting the application, and the two PIs have distinct submission requirements, but both are expected to contribute substantially to key scientific components such as the project narrative and statement of work. If funded, each PI is named on an individual award within the recipient organization, reinforcing the program’s intent to recognize both leadership and partnership. The program also encourages convergence science partnerships, signaling openness to cross-disciplinary teams that combine, for example, biology with engineering, computational approaches, imaging, or novel technology development.

From an eligibility and administrative standpoint, the opportunity is broadly open (listed as “unrestricted,” subject to any clarifications in the full announcement). It is categorized as discretionary funding and supports science and technology/research and development activities under CFDA 12.420. The posting indicates an expected nine awards. The announcement was created April 25, 2022, with an original closing date of October 6, 2022. The award ceiling is shown as 0 in the summary data, which typically means applicants need to rely on the full solicitation text for the actual budget limits and any differences in funding level tied to the Partnering PI option.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Pancreatic Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 25, 2022.
• Applicants must submit their applications by Oct 06, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 9 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PCARP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: